eTheRNA Immunotherapies NV Market Growth, Market Size, Market Outlook : Ken Research
eTheRNA Immunotherapies NV-Pharmaceuticals & Healthcare-Deals and Alliances Profile

eTheRNA Immunotherapies NV-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH2480420D
  • |
  • Pages: 18
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

eTheRNA Immunotherapies NV (eTheRNA) focuses on the development of novel immunotherapies for the treatment of cancers and infectious diseases. Its pipeline portfolio includes mRNA-based immunotherapies for various indications such as melanoma, triple negative breast cancer and infectious diseases. It provides preclinical and clinical proof to support further development of the TriMix technology into an injectable in vivo product. eTheRNA seeks for collaborative partnerships with pharma companies that enables to develop and commercialize the differentiated TriMix-based immunotherapies. It also develops drugs for infectious diseases such as influenza, pneumonia, tuberculosis, Lyme disease, HIV/AIDS et cetera. The company is a spin-off of Vrije Universiteit Brussel. eTheRNA is headquartered in Antwerp, Belgium.

eTheRNA Immunotherapies NV-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deal Details

Venture Financing

eTheRNA Raises USD27 Million in Series A Financing

Partnerships

PCI Biotech Enters Research Agreement with eTheRNA immunotherapies

Licensing Agreements

eTheRNA Enters into Licensing Agreement with Vrije Universiteit Brussel

eTheRNA Immunotherapies NV-Key Competitors

eTheRNA Immunotherapies NV-Key Employees

eTheRNA Immunotherapies NV-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Government and Public Interest

Sep 25, 2017: eTheRNA immunotherapies Awarded �1 Million Grant From Flanders Innovation & Entrepreneurship to Further Upgrade its State-of-the-art Production Process for TriMix mRNA Immunotherapies

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

List of Tables

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Key Facts

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Deals By Therapy Area, 2012 to YTD 2018

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

eTheRNA Raises USD27 Million in Series A Financing

PCI Biotech Enters Research Agreement with eTheRNA immunotherapies

eTheRNA Enters into Licensing Agreement with Vrije Universiteit Brussel

eTheRNA Immunotherapies NV, Key Competitors

eTheRNA Immunotherapies NV, Key Employees

eTheRNA Immunotherapies NV, Other Locations

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com